Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis
- 23 January 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (10), 4258-4263
- https://doi.org/10.1182/blood-2006-08-040774
Abstract
The antithrombin A384S mutation has a relatively high frequency in the British population but has not been identified in other populations. This variant has been associated with cases of thrombotic disease, but its clinical relevance in venous thrombosis remained unclear. We have conducted a secondary analysis of the prevalence of the mutation in a large case-control study, including 1018 consecutive Spanish patients with venous thromboembolism. In addition, we evaluated its functional consequences in 20 carriers (4 homozygous). This mutation, even in the homozygous state, did not affect anti-Xa activity or antigen levels, and it only slightly impaired anti-IIa activity. Thus, routine clinical methods cannot detect this anomaly, and, accordingly, this alteration could have been underestimated. We identified this mutation in 0.2% of Spanish controls. Among patients, this variant represented the first cause of antithrombin anomalies. Indeed, 1.7% patients carried the A384S mutation, but 0.6% had any other antithrombin deficiency. The mutated allele was associated with an increased risk of venous thrombosis with an adjusted OR of 9.75 (95% CI, 2.2-42.5). This is the first study supporting that antithrombin A384S mutation is a prevalent genetic risk factor for venous thrombosis and is the most frequent cause of antithrombin deficiency in white populations.This publication has 25 references indexed in Scilit:
- A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosisBlood, 2006
- Heparin-induced substrate behavior of antithrombin Cambridge IIBlood, 2003
- Genetic Susceptibility to Venous ThrombosisThe New England Journal of Medicine, 2001
- Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assaysBlood Coagulation & Fibrinolysis, 2000
- Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large familyBritish Journal of Haematology, 1999
- Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large familyBritish Journal of Haematology, 1999
- A prospective study of the incidence of deep‐vein thrombosis within a defined urban populationJournal of Internal Medicine, 1992
- Antithrombin Cambridge II, 384 Ala to Ser Further evidence of the role of the reactive centre loop in the inhibitory function of the serpinsFEBS Letters, 1991
- ANTITHROMBIN III ACTIVITY IN HEALTHY BLOOD DONORS: AGE AND SEX RELATED CHANGES AND THE PREVALENCE OF ASYMPTOMATIC DEFICIENCYBritish Journal of Haematology, 1990
- Antithrombin Cambridge, 384 Ala to Pro: A new variant identified using the polymerase chain reactionFEBS Letters, 1989